Skip to main content
. 2025 Dec 18;17(12):1627. doi: 10.3390/pharmaceutics17121627
COVID-19 Coronavirus disease 2019
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
BA Bioavailability
ADME Absorption, distribution, metabolism, and excretion
PXRD Powder X-ray diffraction
PEG 400 Polyethylene glycol 400
PG Propylene glycol
PVPVA Polyvinylpyrrolidone-vinyl acetate
HPMCAS Hydroxypropyl methylcellulose acetate succinate
Cmax Maximum plasma concentration
Tmax Time to maximum plasma concentration
AUC Area under the plasma concentration–time curve
SAD Single ascending dose